Azopharma Product Development Group announced the successful FDA audit of its Cyanta Analytical Laboratories facility in Maryland Heights, MO. The audit occurred from Aug 19-20 and produced no 483s or other major observations.
   
Mr. Phil Meeks, chief executive officer of Azopharma, commented, “We are very pleased with the results of the recent FDA audit. It demonstrates our commitment to quality systems and personnel.”
   
Cyanta Analytical Laboratories is a member of the Azopharma Product Development Group and provides analytical testing to the pharmaceutical, biotechnology and medical device industries. The Cyanta facility was previously audited in 2006 which also produced no 483s or major observations.